Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer

This publication has 24 references indexed in Scilit:

• S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)
  Journal of Biological Chemistry, 2004
• Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells
  Molecular Carcinogenesis, 2003
• Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models
  The Prostate, 2003
• Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
  The Prostate, 1999
• Neuroendocrine differentiation in prostatic carcinoma
  The Prostate, 1999
• ELEVATED LEVELS OF CIRCULATING INTERLEUKIN-6 AND TRANSFORMING GROWTH FACTOR-beta 1 IN PATIENTS WITH METASTATIC PROSTATIC CARCINOMA
  Journal of Urology, 1999
• Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity
  Cancer, 1999
• Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines
  Anti-Cancer Drugs, 1998
• Regulation of S100P expression by androgen
  The Prostate, 1996
• S100P, a novel Ca²⁺ ‐binding protein from human placenta
  European Journal of Biochemistry, 1992